The Gilead Sciences story

What drives the business

• Gilead's foundation is HIV treatment and prevention, spanning daily Biktarvy, Descovy and the twice-yearly Yeztugo injection, alongside a liver disease portfolio that includes hepatitis medicines and Livdelzi.
• The expansion into cancer includes the completed Arcellx acquisition, with an implied equity value of approximately $7.8 billion at closing, which gave Gilead full control of investigational multiple myeloma therapy anito-cel and eliminated future profit-sharing, milestone and royalty obligations.
• Historically, approximately 90% of gross U.S. product sales have gone through Cardinal Health, Cencora and McKesson and their specialty distributor affiliates.
• In the quarter to June 2026, Biktarvy sales rose 7% to $3.8 billion and Descovy rose 48% to $967 million, with higher realized prices and demand supporting both products, while liver disease sales rose 10% to $877 million.
• Cancer growth was uneven in the quarter to June 2026: Trodelvy sales increased 26% to $457 million, while cell therapy sales decreased 14% to $417 million amid competition.

What the price assumes

At $152.21 per share, the reverse DCF implies free cash flow after stock pay grows 4.5% a year for ten years, using a 10.2% discount rate.

That compares with a delivered rate of -3.4% a year over the last 10 years and the TenQ check's bar of 0.3%, which moves the historical record halfway toward 4%.

The 6.9% free cash flow yield passes TenQ's cash yield check, but the implied growth exceeds both the historical record and the check's bar.

Value GILD on your own assumptions

What could change the story

• Total debt of $26.2 billion against $3.2 billion in cash and short-term investments leaves less financial flexibility after the acquisitions, and TenQ's liquidity and interest coverage checks fail.
• Competitive pressure is already reducing cell therapy sales, while the FDA's required boxed warning for approved CAR T-cell therapies identifies the risk of T-cell malignancies following treatment.
• Acquired programs still face clinical and commercial uncertainty, illustrated by the discontinued Trodelvy lung cancer study with Merck and an impairment involving research assets previously acquired from Immunomedics.
• Recent and proposed legislation, including the BIOSECURE Act and ABC Safe Drug Act, could restrict foreign sourcing and disrupt clinical trials, manufacturing and product launches.
• Pricing and reimbursement pressures could affect realized prices, while judicial decisions have increased the risk of False Claims Act litigation over alleged 340B pricing violations.

What to watch next

• For full year 2026, Gilead expects product sales between $30,100 million and $30,400 million, including sales excluding Veklury between $29,800 million and $30,100 million and Veklury sales around $300 million.
• The next releases will show whether Biktarvy and Descovy sustain growth, Trodelvy's expanded breast cancer approvals translate into demand, and cell therapy declines ease.
• Regulatory milestones include an anticipated FDA action date of December 23, 2026 for anito-cel and February 2, 2027 for the potential once-weekly oral Yeztugo formulation.
• Operating cash flow, cash balances and debt will show how Gilead absorbs acquisition spending, while its full year 2026 diluted loss per share guidance of $(3.75) to $(3.40) includes acquisition-related research charges and taxes.

Sources

• Gilead Sciences's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The GILD stock report, for every figure and check